• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    3/21/25 7:55:38 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email
    8-K
    INSULET CORP false 0001145197 0001145197 2025-03-20 2025-03-20

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): March 21, 2025 (March 20, 2025)

    INSULET CORPORATION

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-33462   04-3523891

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

      100 Nagog Park,  
    Acton   Massachusetts   01720

    (Address of Principal Executive Offices, including Zip Code)

    Registrant’s telephone number, including area code: (978) 600-7000

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.            ☐

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 Par Value Per Share   PODD   The NASDAQ Stock Market, LLC


    Item 1.01

    Entry into a Material Definitive Agreement.

    Indenture

    On March 20, 2025 (the “Closing Date”), Insulet Corporation (the “Company”) closed its previously announced issuance and sale of $450 million aggregate principal amount of the Company’s 6.50% Senior Notes due 2033 (the “Notes”). The estimated net proceeds from the offering are expected to be approximately $444 million, after deducting the initial purchasers’ discounts and commissions related to the offering.

    The Notes are governed by the terms of an indenture, dated as of the Closing Date (the “Indenture”), between the Company and Computershare Trust Company, National Association, as trustee (the “Trustee”). The Notes bear interest at a rate of 6.50% per annum, payable semi-annually in arrears on each April 1 and October 1 of each year, commencing on October 1, 2025. The Notes were issued at par. The Notes will mature on April 1, 2033.

    On and after the Closing Date, the Notes will be guaranteed by each of the Company’s direct and indirect wholly owned restricted subsidiaries (subject to certain exceptions) that is a borrower or guarantor under the Company’s Credit Agreement (as defined below), certain other syndicated credit facilities of the Company or any other subsidiary guarantor or certain capital markets debt of the Company or any other subsidiary guarantor, subject to certain exceptions. The Notes and the guarantees thereof will be unsecured, unsubordinated indebtedness of the Company and the guarantors. As of the Closing Date, there will be no guarantors.

    The Indenture contains certain customary covenants and events of default (subject in certain cases to customary grace and cure periods).

    The above description of the Indenture and the Notes is a summary only and is qualified in its entirety by reference to the Indenture, which is attached hereto as Exhibit 4.1 and is incorporated herein by reference.

    Credit Agreement

    On the Closing Date, the Company also entered into the Seventh Amendment to Credit Agreement (the “Amendment”) among the Company, the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (the “Agent”), swingline lender, and letter of credit issuer, amending that certain Credit Agreement, dated as of May 4, 2021 (as previously amended, supplemented or modified, the “Credit Agreement”, and as amended by the Amendment, the “Amended Credit Agreement”), by and among the Company, the lenders and other parties thereto and the Agent.

    The Amendment amended the Credit Agreement to, among other things, extend the maturity of (and terminate any non-extending) revolving credit commitments outstanding thereunder from the earlier of (x) June 9, 2028 and (y) the date that is 91 days prior to the scheduled maturity of the Term B Loans (as defined in the Credit Agreement) to March 20, 2030 and increase the amount of revolving credit commitments outstanding thereunder (such extended and increased revolving credit commitments, collectively, the “New Revolving Commitments”). After giving effect to such transactions, on the Closing Date, the aggregate amount of New Revolving Commitments under the Amended Credit Agreement is $500 million (the “Revolving Credit Facility”), which commitments were undrawn as of such date.

    Proceeds of loans borrowed and letters of credit issued under the Revolving Credit Facility will be used for working capital and other general corporate purposes of the Company and its subsidiaries.

    Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to, at the Company’s option, either (a) an adjusted Term SOFR rate (subject to a 0.00% floor) or (b) a base rate, in each case, plus an applicable margin which varies depending on the Company’s adjusted total leverage ratio, as defined in the Amended Credit Agreement. The applicable margin ranges from (a) 2.00% to 2.50%, in the case of Term SOFR Loans (as defined in the Amended Credit Agreement) and (b) 1.00% to 1.50%, in the case of Base Rate Loans (as defined in the Amended Credit Agreement). The Company is also required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder. The commitment fee under the Revolving Credit Facility varies depending on the Company’s adjusted total leverage ratio and ranges from 0.25% to 0.50%.


    The Company may generally prepay outstanding loans under the Revolving Credit Facility at any time, without prepayment premium or penalty, subject to customary “breakage” costs with respect to Term SOFR loans.

    The Revolving Credit Facility requires that the Company maintain a financial covenant leverage ratio, as defined in the Amended Credit Agreement, of no greater than 6.50 to 1.00 as of the last day of any fiscal quarter on the last day of which the aggregate amount of revolving loans, swingline loans and letters of credit (subject to certain exclusions) outstanding under the Revolving Credit Facility exceeds 35% of the aggregate commitments outstanding thereunder, subject to certain step-ups in connection with certain material acquisitions.

    The foregoing description of the Amendment is not intended to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

    Unwind Agreements

    As previously disclosed, in connection with issuing the Convertible Senior Notes (as defined below), the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain financial institutions (the “Capped Call Counterparties”). In connection with the Note Repurchase Transactions (as defined below), the Company entered into unwind agreements substantially in the form attached hereto as Exhibit 10.2, with each Capped Call Counterparty to terminate a portion of the Capped Call Transactions that corresponds to the amount of Convertible Senior Notes repurchased. In connection with the termination of these transactions, the Company expects the Capped Call Counterparties or their respective affiliates to unwind their related hedge positions, which may involve the sale of shares of the Company’s common stock in the open market or other transactions with respect to the Company’s common stock. This hedge unwind activity could offset the effects of the purchase activity that holders of the Convertible Senior Notes that participated in the Note Repurchase Transactions effected in connection with those transactions as described below.

    The above descriptions of the unwind agreements are a summary only and are qualified in their entirety by reference to the Form of Unwind Agreement, which is attached hereto as Exhibit 10.2, and is incorporated herein by reference.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth above in Item 1.01 of this Current Report on Form 8-K under the headings “Indenture” and “Credit Agreement” is incorporated by reference into this Item 2.03.

     

    Item 7.01

    Regulation FD Disclosure.

    Note Repurchase Transactions

    On the Closing Date, the Company entered into separate and privately negotiated agreements with certain holders of the Company’s outstanding 0.375% Convertible Senior Notes due 2026 (the “Convertible Senior Notes”) pursuant to which the Company agreed to repurchase for cash consideration $419 million aggregate principal amount of the Convertible Senior Notes (such notes, the “Repurchased Notes”, and each such transaction, a “Note Repurchase Transaction”). Certain of the Note Repurchase Transactions will close on March 24, 2025, for a total purchase price of approximately $161.4 million. The remainder of the Note Repurchase Transactions are expected to close on April 14, 2025, following an averaging period beginning on March 21, 2025 that will determine the repurchase price for such Note Repurchase Transactions, for a total purchase price of approximately $382.9 million (assuming the per share volume-weighted average price of the Company’s common stock during each day of the averaging period is $265.39, the closing price of the Company’s common stock on the Closing Date), subject to customary closing conditions, in each case pursuant to separate and individually negotiated agreements with the applicable holders of the Repurchased Notes. Following the closing of the Note Repurchase Transactions, the Company will have approximately $381 million aggregate principal amount of Convertible Senior Notes outstanding. In connection with any Note Repurchase Transaction, the Company expects that holders of the Repurchased Notes who have hedged their equity price risk with respect to such Repurchased Notes will unwind all or part of their hedge positions by buying the Company’s common stock and/or entering into or unwinding various derivative transactions with respect to the Company’s common stock during a period commencing shortly after the Closing Date.


    Item 9.01

    Financial Statements and Exhibits.

     

    (d)

    Exhibits.

     

    Exhibit
    No.
       Description
    4.1    Indenture, dated as of March 20, 2025, between Insulet Corporation and Computershare Trust Company, National Association, as Trustee
    10.1    Seventh Amendment to Credit Agreement, dated March 20, 2025, among Insulet Corporation, Insulet MA Securities Corporation, Morgan Stanley Senior Funding, Inc., as administrative agent, swingline lender, and letter of credit issuer, and the other lenders party thereto.
    10.2    Form of Unwind Agreement
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.

     

        INSULET CORPORATION
    March 21, 2025     By:  

    /s/ John W. Kapples

          John W. Kapples
          Senior Vice President and General Counsel
    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    6/16/2025$365.00Buy
    Truist
    5/30/2025$380.00Buy
    Goldman
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Global Operations Singh Prem exercised 1,257 shares at a strike of $166.62 and sold $698,216 worth of shares (2,327 units at $300.05), decreasing direct ownership by 21% to 4,143 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      6/16/25 4:18:12 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SVP, Chief HR Officer Manea Dan sold $390,065 worth of shares (1,300 units at $300.05), decreasing direct ownership by 13% to 9,090 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      6/16/25 4:16:39 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Director Borio Luciana sold $147,056 worth of shares (481 units at $305.73), decreasing direct ownership by 13% to 3,087 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      6/10/25 4:17:19 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Insulet with a new price target

      Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00

      6/16/25 7:50:27 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Insulet with a new price target

      Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00

      5/30/25 8:41:35 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00

      5/13/25 8:51:02 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

      Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diab

      6/19/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

      Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration represents a major milestone in our commitment to providing innovative solutions for diabetes manage

      6/10/25 8:30:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions throug

      5/23/25 6:01:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    SEC Filings

    See more
    • Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - INSULET CORP (0001145197) (Filer)

      6/9/25 4:47:07 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Insulet Corporation

      SD - INSULET CORP (0001145197) (Filer)

      5/29/25 4:02:08 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INSULET CORP (0001145197) (Filer)

      5/28/25 4:11:16 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      10/7/24 11:37:08 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      2/13/24 5:06:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $PODD
    Financials

    Live finance-specific insights

    See more
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210

      4/3/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

      Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an

      2/20/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care